NCT02283658View on ClinicalTrials.gov

Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

November 14, 2014

Primary Completion Date

June 15, 2016

Study Completion Date

June 21, 2018

Conditions
Ovarian Endometrioid AdenocarcinomaOvarian Seromucinous CarcinomaOvarian Serous CystadenocarcinomaOvarian Serous Surface Papillary AdenocarcinomaRecurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Ovarian Germ Cell TumorRecurrent Primary Peritoneal CarcinomaUndifferentiated Ovarian Carcinoma
Interventions
DRUG

Everolimus

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Letrozole

Given PO

Trial Locations (2)

55905

Mayo Clinic, Rochester

32224-9980

Mayo Clinic in Florida, Jacksonville

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Mayo Clinic

OTHER